Eli Lilly’s Alzheimer’s drug to face safety, dosing scrutiny from FDA advisers 

By / / Finance / 1 minute of reading



im 735118
When a Food and Drug Administration advisory panel meets Monday to size up an Eli Lilly experimental Alzheimer’s drug, questions about safety, selection of patients for treatment, and dosing will be at the fore, documents released Thursday show.



Source link

About The Author

Avatar of Natalie Simon
Natalie Simon is a writer for Incredible USA News. She writes about arts, automotive, travel, and fashion. She also loves to take photos of her dog and cat, who are both named after famous horror movie characters.

Start typing and press enter to search

Scroll to Top